| Therapeutic agent for ophthalmic diseases -> Monitor Keywords |
|
|
 
Therapeutic agent for ophthalmic diseasesRelated Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Extract, Body Fluid, Or Cellular Material Of Undetermined Constitution Derived From Animal Is Active Ingredient, Embryonic Structure (e.g., Embryo Or Fetus, Etc.), Placenta Or Umbilical CordTherapeutic agent for ophthalmic diseases description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20080075787, Therapeutic agent for ophthalmic diseases. Brief Patent Description - Full Patent Description - Patent Application Claims
TECHNICAL FIELD [0001] The invention relates to a therapeutic agent for ophthalmic diseases. More particularly, the invention relates to a therapeutic agent for ophthalmic diseases containing Laennec (trade name) as an active ingredient. BACKGROUND ART [0002] Patients with ophthalmic diseases are increasing recently, such as dry eye and asthenopia due to wide use of television, personal computer, game machine and other digital appliances, and popularity contact lens. Subjective symptoms of dry eye and asthenopia include ocular dryness, irritation, itchiness, blurred vision and failure in adjustment in near or distant visual acuity, which are considered to be caused mainly by disorder of corneal epithelium due to abnormality of lacrimal fluid. Dry eye and asthenopia are diseases causing troubles in daily life, but radical treatment is not known yet. Various substances have been proposed as dry eye remedies (for example, Japanese Patent Application Laid-Open No. 9-194363), but most of them are synthetic products, and biological substances of high safety are being demanded. [0003] Mainly steroids are used as remedy for inflammatorily ophthalmic diseases (for example, meibomian gland dysfunction, Stevens-Johnson syndrome, Sjogren syndrome, uveitis). Steroids are excellent in anti-inflammatory action, but have strong actions and hence severe side effects, and maximum caution is needed in administration, and they cannot be used easily or prescribed for a long period. [0004] Other recent topics are troubles of organs and tissues by active oxygen, and opthalmologic field is no exception, and prevention and treatment of ophthalmic diseases caused by active oxygen (for example, cataract, glaucoma, age-related macular degeneration, optic disc atrophy) are demanded. [0005] In the light of these problems, the inventor closely investigated into substance of high safety of biological nature, effective for prevention and treatment of ophthalmic diseases, and discovered that Laennec is effective and useful for prevention and treatment of various ophthalmic diseases, and completed the invention. That is, the invention presents a therapeutic agent for ophthalmic diseases containing Laennec as an active ingredient and effective for ophthalmic diseases in a wide range including dry eye and inflammatorily ophthalmic diseases. [0006] Laennec is a medicine derived from placenta extract, and used in treatment of chronic hepatic diseases. Laennec was approved as medicine in 1974 in Japan, and is highly evaluated in safety. However, the action of Laennec on ophthalmic disease has not been known yet. DISCLOSURE OF THE INVENTION [0007] The therapeutic agent for ophthalmic diseases of the invention contains Laennec as an active ingredient. Ophthalmic disease includes corneal disorder, dry eye, asthenopia, and inflammatorily ophthalmic disease (for example, meibomian gland dysfunction, Stevens-Johnson syndrome, Sjogren syndrome, uveitis), and ophthalmic diseases caused by active oxygen (for example, cataract, glaucoma, age-related macular degeneration, optic disc atrophy). The therapeutic agent for ophthalmic diseases of the invention is preferably used as oral dose or eye-drops. BRIEF DESCRIPTION OF THE DRAWINGS [0008] FIG. 1 is a drawing showing an example of evaluation method of AD score of biological staining (fluorescein staining, rose-bengal staining). [0009] FIG. 2 is a drawing showing changes in time of radius (r) of curvature of meniscus in Example 4. [0010] FIG. 3 is a drawing showing changes in time of BUT (tear film breakup time) in Example 4. [0011] FIG. 4 is a drawing showing changes in time of AD score in Example 4. [0012] FIG. 5 is a drawing showing changes in time of value of Schirmer's test in Example 4. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS [0013] The therapeutic agent for ophthalmic diseases of the invention contains Laennec as an active ingredient. Laennec injections are already available commercially, and Laennec preparations can be properly manufactured to be suited to the purpose of the invention. [0014] The therapeutic agent for ophthalmic diseases of the invention is preferably administered orally, or used as eye-drops. [0015] Oral preparations can be manufactured in proper dosage by mixing the Laennec injection or freeze-dried powder as required with pharmacologically acceptable additives (for example, carrier, vehicle, diluent), and examples of pharmaceutical preparation include tablet, powder, granule, and capsule. [0016] Eye-drops are formulated by mixing Laennec with purified water, isotonic agent (for example, sodium chloride, glycerin), surface active agent (for example, polysorbate 80, polyoxyethylene alkyl ether), preservative (for example, sodium edetate, sodium sorbate), buffer agent (for example, sodium phosphate), pH regulator (for example, hydrochloric acid, sodium hydroxide), and other customary pharmaceutical components by ordinary methods. The liquid property is preferred to be near neutral pH (pH 5 to 8), and the osmotic pressure is also preferred to be near 1. [0017] The content of Laennec in pharmaceutical preparation may be properly adjusted depending on the dosage form, disease to be treated, and patient's age, body weight, and symptoms. [0018] The effective dose and schedule of administration of the medicine of the invention may be determined empirically, and are known to those skilled in the art. The dose is properly adjusted depending on the route, disease, and patient's age, body weight, and symptoms, and in case of eye-drops, the medicine of about 0.001 to 3% (w/v, same hereinafter), or preferably about 0.01 to 1% is dropped once to several times a day. [0019] For internal use, the dose is selected in a range of 1 to 100 mg/kg body weight, preferably 2.5 to 50 mg/kg body weight, more preferably about 25 mg/kg body weight, which is divided in one to several portions a day. Continue reading about Therapeutic agent for ophthalmic diseases... Full patent description for Therapeutic agent for ophthalmic diseases Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Therapeutic agent for ophthalmic diseases patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Therapeutic agent for ophthalmic diseases or other areas of interest. ### Previous Patent Application: Antimicrobial agents derived from cream Next Patent Application: Diammonium phosphate and other ammonium salts and their use in preventing clotting Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Therapeutic agent for ophthalmic diseases patent info. IP-related news and info Results in 0.13051 seconds Other interesting Feshpatents.com categories: Tyco , Unilever , Warner-lambert , 3m 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
